Skip to main content

Table 1 Demographic and baseline characteristics

From: Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents

  Total n = 190 Saxagliptin n = 66 Vildagliptin n = 63 Sitagliptin n = 61 p value
Age (years), mean ± SD 46.6 ± 9.0 46.5 ± 10.7 44.8 ± 8.5 48.6 ± 11.3 0.90
Range 23 ~ 72 23 ~ 72 25 ~ 63 29 ~ 70 -
Age (years), n (%)
<50 years 53(28%) 18(27%) 18(29%) 17(27%) 0.99
50 ~ 65 years 90(47%) 31(47%) 29(46%) 30(50%) 0.94
>65 years 47(25%) 17(26%) 16(25%) 14(23%) 0.93
Gender, n (%)
Male 109(57%) 39(59%) 37(59%) 33(54%) 0.82
Female 81(43%) 27(41%) 26(41%) 28(46%) 0.82
Duration of diabetes (years), n (%)
<1 year 61(32%) 20(30%) 24(38%) 17(28%) 0.44
1 ~ 5 years 69(36%) 24(37%) 21(33%) 24(40%) 0.79
>5 years 60(32%) 22(33%) 18(29%) 20(32%) 0.82
Body weight (kg), mean ± SD 74.4 ± 11.1 77.2 ± 15.1 72.7 ± 11.3 73.2 ± 10.9 0.89
BMI (kg/m2), mean ± SD 26.3 ± 2.8 26.9 ± 3.1 25.3 ± 2.8 26.6 ± 3.3 0.80
HbA1c (%), mean ± SD 8.72 ± 1.01 8.86 ± 1.13 8.75 ± 1.15 8.54 ± 1.19 0.94
FBG (mmol/l), mean ± SD 8.46 ± 1.61 8.36 ± 2.04 8.79 ± 1.80 8.22 ± 1.77 0.93
P2hBG(mmol/l), mean ± SD 11.58 ± 2.49 11.77 ± 3.07 11.98 ± 2.46 10.98 ± 2.93 0.90
Therapy, n (%)
Metformin with glimepiride 77(41%) 26(40%) 26(41%) 25(41%) 0.97
Metformin with acarbose 62(33%) 22(33%) 20(32%) 20(33%) 0.98
Metformin with pioglitazone 51(26%) 18(27%) 17(27%) 16(26%) 0.99
  1. Abbreviations: BMI body mass index; FBG fasting blood glucose; P2hBG postprandial 2 hours’ blood glucose.
  2. Data are presented as mean ± standard deviation, as well as, n and%.